MGMT in colorectal cancer: a promising component of personalized treatment

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11443-11456

  Zhang, Le ^a,b   Zeng, Jing ^a   Zeng, Zhaolei ^a   Wang, Fenghua ^a   Wang, Deshen ^a   Chen, Cui ^a   Li, Cong ^a   An, Xin ^a   Xu, Ruihua ^a   Huang, Peng ^a,c   Ba, Yi ^b   Li, Yuhong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Immunohistochemistry; MGMT; Temozolomide

Indexed keywords

AZACITIDINE; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION ASSAY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; HCT116 CELL LINE; HT29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOVO CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; SIGNET RING CARCINOMA; SW620 CELL LINE; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRECISION MEDICINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR SUPPRESSOR PROTEINS;

EID: 84961825409     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5014-1     Document Type: Article

References (29)

1. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. doi:10.1056/NEJMoa0805019.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. doi:10.1056/NEJMoa032691.
3. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):2013–9. doi:10.1200/JCO.2007.14.9930.
4. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(33):5326–34. doi:10.1200/JCO.2008.16.3212.
5. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–75. doi:10.1016/j.ejca.2012.02.057.
6. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(2):229–37. doi:10.1200/JCO.2004.05.113.
7. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi:10.1016/S0140-6736(12)61900-X.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi:10.1056/NEJMoa043331.
9. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus. 2006;20(4):E6. doi:10.3171/foc.2006.20.4.3.
10. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(25):4189–99. doi:10.1200/JCO.2007.11.5964.
11. Natarajan AT, Vermeulen S, Darroudi F, Valentine MB, Brent TP, Mitra S, et al. Chromosomal localization of human O6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis. 1992;7(1):83–5.
12. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296–307. doi:10.1038/nrc1319.
13. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(10):e262–5. doi:10.1200/JCO.2010.32.0242.
14. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990;87(14):5368–72.
15. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991;51(13):3367–72.
16. Jones PA. Altering gene expression with 5-azacytidine. Cell. 1985;40(3):485–6.
17. Taylor SM, Constantinides PA, Jones PA. 5-Azacytidine, DNA methylation, and differentiation. Curr Top Microbiol Immunol. 1984;108:115–27.
18. Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep. 1987;71(10):959–64.
19. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer J Int Cancer. 2008;122(11):2429–36. doi:10.1002/ijc.23398.
20. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(16):2690–8. doi:10.1200/JCO.2007.15.5580.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.
22. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. doi:10.1016/S1470-2045(09)70025-7.
23. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995;55(11):2279–83.
24. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control CCC. 2011;22(2):301–9. doi:10.1007/s10552-010-9698-z.
25. Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. Mod Pathol Off J US Can Acad Pathol Inc. 2012;25(7):1040–7. doi:10.1038/modpathol.2012.44.
26. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97(18):1330–8. doi:10.1093/jnci/dji275.
27. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001;61(3):827–30.
28. Okamoto R, Takano H, Okamura T, Park JS, Tanimoto K, Sekikawa T, et al. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Japanese J Cancer Res Gann. 2002;93(1):93–102.
29. Kuo CC, Liu JF, Chang JY. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther. 2006;316(2):946–54. doi:10.1124/jpet.105.095919.